Age-associated comorbidities can influence immunologic, but not virologic outcomes of cART


  • Agenzia Zoe
  • Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Key messages

  • An influence of age-associated comorbidities on therapeutic outcomes of cART was hypothesized because of additive negative effects of these health conditions in HIV-positive patients older than 50 years
  • Presence of age-associated comorbidities in HIV-positive adults did not affect virological outcomes of cART
  • Patients

 

Combination antiretroviral therapy (cART), has dramatically improved the survival for people living with HIV and, by the end of 2013, those older than 50 years were over 4 million. In this study, the authors investigated the effects of age-associated comorbidities on therapeutic outcomes of cART in HIV-positive adults in Asian countries.

Subjects were selected among patients enrolled, from 2003 to 2015, in TAHOD (TREAT Asia HIV Observational Database), a prospective, observational cohort study (contributing to IeDEA Asia-Pacific) of HIV-positive adults. Patients, were included if they had been on cART for more than 6 months. They were grouped into 4 categories according to their age and comorbidities: age

Comorbidities evaluated included hypertension, diabetes, dyslipidaemia and impaired renal function. The percentage of each was similar among the groups.

In the first group, 912 (17%) patients experienced virological failure, with an incidence rate of 7.72/100 person-years. On univariate analysis, patients aged

In the second group, 391 (7%) patients had immunological failure, with an incidence rate of 2.75/100 person-years. In the multivariate analyses, those aged

Limitations: comorbidities were probably present but not detected because of poor clinic attendance. Authors did not assess the effects of other comorbidities.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit